Alkalinization
Analgesics..
Antiandrogens..
Bromhexine
Budesonide
Cannabidiol
Colchicine
Conv. Plasma
Curcumin
Ensovibep
Famotidine
Favipiravir
Fluvoxamine
Hydroxychlor..
Iota-carragee..
Ivermectin
Lactoferrin
Lifestyle..
Melatonin
Metformin
Molnupiravir
Monoclonals..
Nigella Sativa
Nitazoxanide
Nitric Oxide
Paxlovid
Peg.. Lambda
Povidone-Iod..
Quercetin
Remdesivir
Vitamins..
Zinc

Other
Feedback
Home
Home   COVID-19 treatment studies for Hydroxychloroquine  COVID-19 treatment studies for HCQ  C19 studies: HCQ  HCQ   Select treatmentSelect treatmentTreatmentsTreatments
Alkalinization Meta Lactoferrin Meta
Melatonin Meta
Bromhexine Meta Metformin Meta
Budesonide Meta Molnupiravir Meta
Cannabidiol Meta
Colchicine Meta Nigella Sativa Meta
Conv. Plasma Meta Nitazoxanide Meta
Curcumin Meta Nitric Oxide Meta
Ensovibep Meta Paxlovid Meta
Famotidine Meta Peg.. Lambda Meta
Favipiravir Meta Povidone-Iod.. Meta
Fluvoxamine Meta Quercetin Meta
Hydroxychlor.. Meta Remdesivir Meta
Iota-carragee.. Meta
Ivermectin Meta Zinc Meta

Other Treatments Global Adoption
All Studies   Meta Analysis   Recent:  
0 0.5 1 1.5 2+ Mortality -57% Improvement Relative Risk Ventilation -115% 9-point scale clinical status -147% c19hcq.org Réa-Neto et al. NCT04420247 HCQ RCT LATE TREATMENT Is late treatment with HCQ beneficial for COVID-19? RCT 105 patients in Brazil Higher ventilation (p=0.03) and worse recovery (p=0.02) Réa-Neto et al., Scientific Reports, doi:10.1038/s41598-021-88509-9 Favors HCQ Favors control
An open-label randomized controlled trial evaluating the efficacy of chloroquine/hydroxychloroquine in severe COVID-19 patients
Réa-Neto et al., Scientific Reports, doi:10.1038/s41598-021-88509-9, NCT04420247 (history)
Réa-Neto et al., An open-label randomized controlled trial evaluating the efficacy of chloroquine/hydroxychloroquine in severe.., Scientific Reports, doi:10.1038/s41598-021-88509-9, NCT04420247
Apr 2021   Source   PDF  
  Twitter
  Facebook
Share
  All Studies   Meta
Early terminated very late stage (99% on oxygen, 81% in ICU, 18% on mechanical ventilation at baseline) RCT with 24 CQ patients, 29 HCQ, and 52 control patients, showing worse clinical outcomes with treatment. NCT04420247 (history).
risk of death, 57.0% higher, RR 1.57, p = 0.20, treatment 16 of 53 (30.2%), control 10 of 52 (19.2%).
risk of mechanical ventilation, 115.0% higher, RR 2.15, p = 0.03, treatment 53, control 52.
9-point scale clinical status, 147.0% higher, OR 2.47, p = 0.02, treatment 53, control 52, RR approximated with OR.
Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates
Réa-Neto et al., 27 Apr 2021, Randomized Controlled Trial, Brazil, peer-reviewed, 6 authors, average treatment delay 8.0 days, trial NCT04420247 (history).
All Studies   Meta Analysis   Submit Updates or Corrections
This PaperHCQAll
Abstract: www.nature.com/scientificreports OPEN An open‑label randomized controlled trial evaluating the efficacy of chloroquine/ hydroxychloroquine in severe COVID‑19 patients Álvaro Réa‑Neto1*, Rafaella Stradiotto Bernardelli2, Bruna Martins Dzivielevski Câmara2, Fernanda Baeumle Reese2, Marcos Vinicius Oliveira Queiroga2 & Mirella Cristine Oliveira2 Despite several studies designed to evaluate the efficacy of chloroquine and hydroxychloroquine in the treatment of coronavirus disease 2019 (COVID-19), there is still doubt about the effects of these drugs, especially in patients with severe forms of the disease. This randomized, open-label, controlled, phase III trial assessed the efficacy of chloroquine or hydroxychloroquine for five days in combination with standard care compared to standard care alone in patients hospitalized with severe COVID-19. Chloroquine 450 mg BID on day 1 and 450 mg once daily from days 2 to 5 or hydroxychloroquine 400 mg BID on day 1 and 400 mg once daily from days 2 to 5 were administered in the intervention group. Patients were enrolled from April 16 to August 06, 2020, in 6 hospitals in southern Brazil. The primary outcome was the clinical status measured on day 14 after randomization with a 9-point ordinal scale. The main secondary outcomes were all-cause mortality; invasive mechanical ventilation use; the incidence of acute renal dysfunction in 28 days; and the clinical status of patients on days 5, 7, 10 and 28. All patients with a positive RT-PCR result for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) were analyzed (modified intention to treat (mITT) population). Arrythmias and cardiovascular complications were assessed as safety outcomes. A total of 105 patients were enrolled and followed for 28 days. The trial was stopped before reaching the planned sample size due to harmful effects. Patients in the intervention group had a worse clinical outcome on the 14th day (odds ratio (OR) 2.45 [1.17 to 4.93], p = 0.016) and on the 28th day (OR 2.47 [1.15 to 5.30], p = 0.020). Moreover, the intervention group had higher incidences of invasive mechanical ventilation use (risk ratio (RR) 2.15 [1.05 to 4.40], p = 0.030) and severe renal dysfunction (KDIGO stage 3) (RR 2.24 [1.01 to 4.99], p = 0.042) until the 28th day of follow-up. No significant arrythmia was noted. In patients with severe COVID-19, the use of chloroquine/hydroxychloroquine added to standard treatment resulted in a significant worsening of clinical status, an increased risk of renal dysfunction and an increased need for invasive mechanical ventilation. Trial Registration: ClinicalTrials.gov, NCT04420247. Registered 09 June 2020—Retrospectively registered, https://​www.​clini​caltr​ials.​gov/​ct2/​show/​study/​NCT04​420247. The novel coronavirus, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), causing coronavirus disease 2019 (COVID-19), has already infected tens of millions of people around the world and killed more than a million people (approximately 3%)1. Patients with risk factors or severe forms of COVID-19 have more than a 30% chance of dying. Many antiviral or anti-inflammatory drugs have been studied to find a way to control the poor outcomes of COVID-192. Some drugs have demonstrated in vitro activity against SARS-CoV-2 and potential clinical benefits in small and/or observational ­studies3. In this scenario, experiments with chloroquine (Clq) and its derivative hydroxychloroquine (HClq) revealed that these drugs..
Late treatment
is less effective
Please send us corrections, updates, or comments. Vaccines and treatments are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment, vaccine, or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop   
Submit